ClinicalTrials.gg
CompletedNCT02777970DAVIDUpdated Mar 24, 2021Results posted

Tramadol Hydrochloride and Dexketoprofen Trometamol for the Oral Treatment of Moderate to Severe Acute Pain Following Removal of Impacted Lower Third Molar

A Phase 4 interventional study of Tramadol Hydrochloride/Dexketoprofen Trometamol and Tramadol Hydrochloride/Paracetamol in Acute Pain, sponsored by Menarini Group. Completed at 18 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-24.

Sponsored by Menarini Group · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
654
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing tramadol in Acute Pain — none open to participants now, 1 under way, none of them phase 3. Tramadol · Acute Pain.

Enrollment
4th of 10
654 · median 263
Started
2016
with 3 others
Phase 4
3 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
1 of 10
Menarini Group

Among the 10 studies testing tramadol in Acute Pain, this one is the 4th largest by enrollment, is one of 4 that started in 2016, is one of 3 in phase 4, and was the 2nd registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

None of the 10 studies testing tramadol in Acute Pain is open now. The open studies under Acute Pain, anywhere →

About tramadol

Tramadol: first FDA approval 1995 (ULTRAM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing tramadol in Acute Pain as a file.
02

Study summary

The study is aimed to evaluate the analgesic efficacy of TRAM.HCl/DKP.TRIS 75mg/25mg oral fixed drug combination in comparison with TRAM.HCl /paracetamol 75mg/650mg in the treatment of moderate to severe acute pain.

Read the detailed description

The present phase IV study is a randomised, double-blind, placebo and active-controlled, parallel group study in moderate to severe acute pain after removal of impacted lower third molar.

In this single-dose clinical trial patients are randomized to the following 3 treatment arms in a 2:2:1 ratio:

  • TRAM.HCL/DKP.TRIS
  • Paracetamol/TRAM.HCL
  • Placebo.
03

Conditions studied

  • Acute Pain

Keywords

  • Acute pain
  • Acute moderate to severe pain
  • Postoperative pain
  • Dexketoprofen Tramadol
  • Dexketoprofen trometamol
  • Tramadol hydrochloride
  • Multimodal analgesia
  • Third molar extraction
  • Fixed drug combination
  • Paracetamol
  • Analgesics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged more than 18 years. Females participating in the study must be either non- or routinely using an effective method of resulting in a low failure rate.
  • Scheduled for outpatient surgical extraction -under local anaesthesia of lower third molar teeth, with at least one partially impacted in the mandible requiring bone manipulation.
  • Pain of at least moderate intensity in the first 4 hours after the end of surgery (NRS score ≥ 4).

Exclusion criteria

Exclusion Criteria:

  • History of allergy or to the study treatments, RM or to any other NSAIDs, opioids and acetyl salicylic acid.
  • History of peptic ulcer, gastrointestinal disorders by NSAIDs or gastrointestinal bleeding or other active bleedings.
  • History of any illness or condition that, in the opinion of the Investigator might pose a risk to the patient or confound the efficacy and safety results of the study.
  • Patients using and not suitable for withdrawing the prohibited medications specified in the protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
654 participants (actual)

Study arms

  • Experimental
    Tramadol/Dexketoprofen

    Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose; Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x \[37.5mg/325mg\] film-coated tablets, oral single dose.

    Drug: Tramadol Hydrochloride/Dexketoprofen Trometamol · Drug: Placebo

  • Active comparator
    Tramadol/Paracetamol

    Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x \[37.5mg/325mg\] film-coated tablets, oral single dose; Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose. .

    Drug: Tramadol Hydrochloride/Paracetamol · Drug: Placebo

  • Placebo comparator
    Placebo

    Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose; Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. TOTPAR6 (Total Pain Relief Over 6 Hours Post-dose)

    TOTPAR calculated as the weighted sum of the PAR scores, measured according to a 5-point VRS (Verbal Rating Scale) from 0=no relief to 4=complete relief, over 6 hours post-dose (TOTPAR6). The TOTPAR6 ranges from a minimum of 0 to a maximum of 24.

    Time frame: 6 hours post-dose

Secondary outcomes

  1. % of Patients Achieving 50% of Max TOTPAR

    Percentage of patients who achieved at least 50% of the maximum TOTPAR at 8 hours. In the present trial the achievable TOTPAR over 8 hours ranges between 0 and 32."

    Time frame: 8 hours post-dose

  2. % of Patients Achieving at Least 30% of PI (Pain Intensity) Reduction Over 8 Hours Post-dose

    Percentage of patients who achieve at least 30% of PI Reduction versus baseline Over 8 Hours Post-dose. Percentage change of PI is calculated using the baseline value minus the PI assessed at 8 hours post-dose divided for the baseline value, then multiplied for 100.

    Time frame: 8 hours post-dose

  3. Time to Confirmed FPPAR (First Perceptible Pain Relief)

    Time to confirmed FPPAR (time to onset of analgesia) - i.e. time to FPPAR if confirmed by experiencing Meaningful Pain Relief (MPAR) FPPAR and MPAR assessed by using stopwatches: 1. 'first perceptible' PAR (FPPAR), i.e, at the moment they first felt any PAR whatsoever; 2. 'meaningful' PAR (MPAR, ie, when the relief from pain became meaningful to them)

    Time frame: 2 hours post-dose

  4. % of Patients Requiring RM (Rescue Medication)

    Percentage of patients who required RM within the first over 8 hours post-dose.

    Time frame: 8 hours post-dose

  5. PGE (Patient Global Evaluation)

    PGE of the study medication (measured according to a five-point VRS from 1 = poor to 5 = excellent) at 8 hours post-dose or whenever the patient uses Rescue Medication (RM).

    Time frame: 8 hours postdose

07

Results

Posted Mar 24, 2021

Participant flow

This study was conducted in 18 centers across 5 European countries: Hungary, Italy, Poland, Spain and the United Kingdom. The clinical phase of the study started on 28th April 2016 (first screened patient) and concluded on 14th February 2017 (last patient out).

Participant flow — Overall Study
MilestoneTramadol/DexketoprofenTramadol/ParacetamolPlacebo
Started261262131
Completed260261131
Not completed110
Withdrew: Lost to follow-up010
Withdrew: Protocol violation100

Outcome measures

PrimaryTOTPAR6 (Total Pain Relief Over 6 Hours Post-dose)

TOTPAR calculated as the weighted sum of the PAR scores, measured according to a 5-point VRS (Verbal Rating Scale) from 0=no relief to 4=complete relief, over 6 hours post-dose (TOTPAR6). The TOTPAR6 ranges from a minimum of 0 to a maximum of 24.

Time frame:
6 hours post-dose
Reported as:
Mean · 5-point Verbal Rating Scale
TOTPAR6 (Total Pain Relief Over 6 Hours Post-dose)
5-point Verbal Rating ScaleTramadol/DexketoprofenTramadol/ParacetamolPlacebo
TOTPAR6 (Total Pain Relief Over 6 Hours Post-dose)13.0 ± 6.979.2 ± 7.651.9 ± 3.89
Secondary% of Patients Achieving 50% of Max TOTPAR

Percentage of patients who achieved at least 50% of the maximum TOTPAR at 8 hours. In the present trial the achievable TOTPAR over 8 hours ranges between 0 and 32."

Time frame:
8 hours post-dose
Reported as:
Number · percentage of patients
% of Patients Achieving 50% of Max TOTPAR
percentage of patientsTramadol/DexketoprofenTramadol/ParacetamolPlacebo
% of Patients Achieving 50% of Max TOTPAR47.735.55.3
Secondary% of Patients Achieving at Least 30% of PI (Pain Intensity) Reduction Over 8 Hours Post-dose

Percentage of patients who achieve at least 30% of PI Reduction versus baseline Over 8 Hours Post-dose. Percentage change of PI is calculated using the baseline value minus the PI assessed at 8 hours post-dose divided for the baseline value, then multiplied for 100.

Time frame:
8 hours post-dose
Reported as:
Number · percentage of patients
% of Patients Achieving at Least 30% of PI (Pain Intensity) Reduction Over 8 Hours Post-dose
percentage of patientsTramadol/DexketoprofenTramadol/ParacetamolPlacebo
% of Patients Achieving at Least 30% of PI (Pain Intensity) Reduction Over 8 Hours Post-dose40.035.59.9
SecondaryTime to Confirmed FPPAR (First Perceptible Pain Relief)

Time to confirmed FPPAR (time to onset of analgesia) - i.e. time to FPPAR if confirmed by experiencing Meaningful Pain Relief (MPAR) FPPAR and MPAR assessed by using stopwatches: 1. 'first perceptible' PAR (FPPAR), i.e, at the moment they first felt any PAR whatsoever; 2. 'meaningful' PAR (MPAR, ie, when the relief from pain became meaningful to them)

Time frame:
2 hours post-dose
Reported as:
Median · minutes
Time to Confirmed FPPAR (First Perceptible Pain Relief)
minutesTramadol/DexketoprofenTramadol/Paracetamol
Time to Confirmed FPPAR (First Perceptible Pain Relief)21 (17 to 23)24 (20 to 27)
Secondary% of Patients Requiring RM (Rescue Medication)

Percentage of patients who required RM within the first over 8 hours post-dose.

Time frame:
8 hours post-dose
Reported as:
Number · percentage of patients
% of Patients Requiring RM (Rescue Medication)
percentage of patientsTramadol/DexketoprofenTramadol/ParacetamolPlacebo
% of Patients Requiring RM (Rescue Medication)51.255.088.5
SecondaryPGE (Patient Global Evaluation)

PGE of the study medication (measured according to a five-point VRS from 1 = poor to 5 = excellent) at 8 hours post-dose or whenever the patient uses Rescue Medication (RM).

Time frame:
8 hours postdose
Reported as:
Mean · units on a scale
PGE (Patient Global Evaluation)
units on a scaleTramadol/DexketoprofenTramadol/ParacetamolPlacebo
PGE (Patient Global Evaluation)3.6 ± 1.12.8 ± 1.41.5 ± 0.9

Adverse events

Collected over Reported treatment emergent AEs (TEAEs) include events starting after administration of study drug on or after Day 1 and on or before end of study visit Day 6+/- 1.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tramadol/Dexketoprofen0/260 (0%)1/260 (0.4%)35/260 (13.5%)
Tramadol/Paracetamol0/262 (0%)0/262 (0%)40/262 (15.3%)
Placebo0/131 (0%)0/131 (0%)13/131 (9.9%)
Most frequent serious events
Most frequent serious events
EventTramadol/DexketoprofenTramadol/ParacetamolPlacebo
SyncopeNervous system disorders1/2600/2620/131
Most frequent other events
Most frequent other events
EventTramadol/DexketoprofenTramadol/ParacetamolPlacebo
VomitingGastrointestinal disorders11/26014/2620/131
DizzinessNervous system disorders6/26013/2620/131
NauseaGastrointestinal disorders10/26011/2620/131
Postoperative wound infectionInfections and infestations8/2602/2622/131
Face oedemaGeneral disorders3/2608/2624/131
SomnolenceNervous system disorders7/2604/2621/131
Procedural painInjury, poisoning and procedural complications3/2605/2623/131
HaematomaVascular disorders2/2600/2623/131

Baseline characteristics

Intention-to-treat (ITT) population: all patients randomized.

Age, Continuous
Age, Continuous(years)Tramadol/DexketoprofenTramadol/ParacetamolPlaceboTotal
Mean26.8 ± 7.4827.1 ± 8.1326.5 ± 7.6726.9 ± 7.78
Sex: Female, Male
Sex: Female, Male(Participants)Tramadol/DexketoprofenTramadol/ParacetamolPlaceboTotal
Female15210453309
Male10815878344
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tramadol/DexketoprofenTramadol/ParacetamolPlaceboTotal
White235233118586
Asian1421641
Black or Afro-american73616
Other45110
Pain Intensity at Qualification
Pain Intensity at Qualification(units on a scale)Tramadol/DexketoprofenTramadol/ParacetamolPlaceboTotal
Mean5.0 ± 1.194.9 ± 1.124.8 ± 1.104.9 ± 1.14
08

Study locations

18 sites
  • Dr. Tóth Bagi Zoltán Fogászati Rendeloje
    Budapest, 1052, Hungary
  • OralMed Studio Fogászati és Szájsebészeti Kft.
    Budapest, 1126, Hungary
  • Szegedi Tudományegyetem
    Szeged, 6725, Hungary
  • Ospedale Civile San Salvatore di L'Aquila
    L'Aquila, 67100, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • Azienda Ospedaliero-Universitaria Pisana
    Pisa, 56126, Italy
  • Azienda Ospedaliera Universitaria Integrata
    Verona, 37134, Italy
  • Ars-Dent
    Bialystok, 15-078, Poland
  • Gabinet Stomatologiczny Andrzej Wojtowicz AW Clinic
    Warszawa, 00-852, Poland
  • Charme Clinique Klinika Stomatologii
    Warszawa, 02-670, Poland
  • Centro Medico Teknon
    Barcelona, 08022, Spain
  • Hospital Médico Quirúrgico de Conxo
    La Coruna, 15702, Spain
  • Hospital Universitario Virgen del Rocío
    Sevilla, 41009, Spain
  • Universidad de Valencia
    Valencia, 46010, Spain
  • Birmingham Community Healthcare NHS Foundation Trust
    Birmingham, B4 6NN, United Kingdom
  • University Hospital of Wales
    Cardiff, CF14 4XT, United Kingdom
  • University of Manchester
    Manchester, M15 6FH, United Kingdom
  • University Hospitals of North Midlands NHS Trust
    Stoke on Trent, ST4 6QG, United Kingdom
09

References and documents

Publications

  • Gay-Escoda C, Hanna M, Montero A, Dietrich T, Milleri S, Giergiel E, Zoltan TB, Varrassi G. Tramadol/dexketoprofen (TRAM/DKP) compared with tramadol/paracetamol in moderate to severe acute pain: results of a randomised, double-blind, placebo and active-controlled, parallel group trial in the impacted third molar extraction pain model (DAVID study). BMJ Open. 2019 Feb 19;9(2):e023715. doi: 10.1136/bmjopen-2018-023715. Erratum In: BMJ Open. 2019 Jun 14;9(6):e023715corr1. doi: 10.1136/bmjopen-2018-023715corr1. PubMed 30782886 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Feb 2017, 10 months.

Results were first posted in Mar 2021, 4 years 1 month after primary completion.

Of 84 phase 4 interventional studies under Acute Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2016
First posted
May 19, 2016
StartActual
Apr 2016
Primary completionActual
Feb 14, 2017
CompletionActual
Feb 14, 2017
Results first posted
Mar 24, 2021
Last update
Mar 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02777970
Lead sponsor
Menarini Group
Responsible party
Sponsor
First posted
May 19, 2016
Start date
Apr 2016
Primary completion
Feb 14, 2017
Completion
Feb 14, 2017
Results posted
Mar 24, 2021
Last update
Mar 24, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tramadol · Dexketoprofen

Start the discussion